|
|
|
|
Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania (V.J.F., D.M.T., K.D.T.); Basic Research Program, SAIC-Frederick, Frederick, Maryland (J.E.S., G.S.B., M.L.C.); and Laboratory of Comparative Carcinogenesis (L.K.K.) and Macromolecular Crystallography Laboratory (X.J.), National Cancer Institute at Frederick, Frederick, Maryland
We have used structure-based design techniques to introduce the drug O2-[2,4-dinitro-5-(N-methyl-N-4-carboxyphenylamino) phenyl] 1-N,N-dimethylamino)diazen-1-ium-1,2-diolate (PABA/NO), which is efficiently metabolized to potentially cytolytic nitric oxide by the
isoform of glutathione S-transferase, an enzyme expressed at high levels in many tumors. We have used mouse embryo fibroblasts (MEFs) null for GST
(GST
-/-) to show that the absence of GST
results in a decreased sensitivity to PABA/NO. Cytotoxicity of PABA/NO was also examined in a mouse skin fibroblast (NIH3T3) cell line that was stably transfected with GST
and/or various combinations of
-glutamyl cysteine synthetase and the ATP-binding cassette transporter MRP1. Overexpression of MRP1 conferred the most significant degree of resistance, and in vitro transport studies confirmed that a GST
-activated metabolite of PABA/NO was effluxed by MRP1 in a GSH-dependent manner. Additional studies showed that in the absence of MRP1, PABA/NO activated the extracellular-regulated and stress-activated protein kinases ERK, c-Jun NH2-terminal kinase (JNK), and p38. Selective inhibition studies showed that the activation of JNK and p38 were critical to the cytotoxic effects of PABA/NO. Finally, PABA/NO produced antitumor effects in a human ovarian cancer model grown in SCID mice.
Address correspondence to: Kenneth D. Tew, Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111. E-mail: kd_tew{at}fccc.edu
This article has been cited by other articles:
![]() |
D. M. Townsend, Y. Manevich, L. He, S. Hutchens, C. J. Pazoles, and K. D. Tew Novel Role for Glutathione S-Transferase {pi}: REGULATOR OF PROTEIN S-GLUTATHIONYLATION FOLLOWING OXIDATIVE AND NITROSATIVE STRESS J. Biol. Chem., January 2, 2009; 284(1): 436 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Townsend, L. He, S. Hutchens, T. E. Garrett, C. J. Pazoles, and K. D. Tew NOV-002, a Glutathione Disulfide Mimetic, as a Modulator of Cellular Redox Balance Cancer Res., April 15, 2008; 68(8): 2870 - 2877. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Townsend S-Glutathionylation: Indicator of Cell Stress and Regulator of the Unfolded Protein Response Mol. Interv., December 1, 2007; 7(6): 313 - 324. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Moyer, O. E. Salavaggione, S. J. Hebbring, I. Moon, M. A.T. Hildebrandt, B. W. Eckloff, D. J. Schaid, E. D. Wieben, and R. M. Weinshilboum Glutathione S-Transferase T1 and M1: Gene Sequence Variation and Functional Genomics Clin. Cancer Res., December 1, 2007; 13(23): 7207 - 7216. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. J. Findlay, D. M. Townsend, T. E. Morris, J. P. Fraser, L. He, and K. D. Tew A Novel Role for Human Sulfiredoxin in the Reversal of Glutathionylation. Cancer Res., July 1, 2006; 66(13): 6800 - 6806. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Townsend, V. J. Findlay, F. Fazilev, M. Ogle, J. Fraser, J. E. Saavedra, X. Ji, L. K. Keefer, and K. D. Tew A Glutathione S-Transferase {pi}-Activated Prodrug Causes Kinase Activation Concurrent with S-Glutathionylation of Proteins Mol. Pharmacol., February 1, 2006; 69(2): 501 - 508. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Tew, J. T. Boyd, Z. J. Chen, W. Davis Jr., F. Fazilev, V. Findlay, L. Gate, K. Ile, A. Soulika, and D. M. Townsend Glutathione and ABC Transporters as Determinants of Sensitivity to Oxidative and Nitrosative Stress J. Nutr., November 1, 2004; 134(11): 3205S - 3206S. [Full Text] [PDF] |
||||